First-Line Helicobacter pylori Eradication with Vonoprazan, Clarithromycin, and Metronidazole in Patients Allergic to Penicillin

Table 1

Patient backgrounds.

	VCM	PCM
Age	69.0 ± 10.2	66.5 ± 8.5
Male, %	20.0	53.3
CAM 200 bid, %	80.0	96.7
Evaluation by UBT, %	100	93.3
Endoscopic findings, %
Gastroduodenal ulcer	10.0	40.0
Gastric cancer	5.0	3.3
Gastric adenoma	0	3.3
MALT	5.0	0
Gastritis only	80.0	53.3
Diagnosis of infection
HpIgG	30.0	43.3
RUT	20.0	20.0
Culture	25.0	3.3
Pathology	5.0	30.0
UBT	10.0	3.3
Urine, stool antigen	10.0	0

VCM: vonoprazan/CAM/MNZ 1-week eradication therapy; PCM: PPI (LPZ or ESO)/CAM/MNZ 1-week eradication therapy; CAM 200 bid, %: percentage of CAM 200 mg twice per day (400 mg/day) against CAM 400 mg twice per day (800 mg/day); evaluation by UBT, %: percentage determined by ¹³C-urea breath test versus H. pylori stool antigen test; endoscopic findings: all participants underwent endoscopy before eradication therapy; RUT: rapid urease test; UBT: ¹³C-urea breath test.